Gemma Louise Clayton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gemma Louise Clayton has a total of 324 co-authors. Here are the top co-authors by number of shared publications:
- Debbie A. Lawlor
MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
11 shared publications Deborah A Lawlor
MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
8 shared publications- Abigail Fraser
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England, UK
7 shared publications - Maria Carolina Borges
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
6 shared publications - Abi Merriel
University of Liverpool, UK
5 shared publications - Ana Luiza Gonçalves Soares
MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
5 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Which Is The Best Method For Induction Of Labour In Low- And Middle-Income Countries?: A Systematic Review And Network Meta-Analysis
Background: Globally, induction of labour rates and methods vary according to resource setting. Our aim is to identify the most effective induction of labour method for achieving vaginal birth within 24 hours in low- and middle-income settings without increasing adverse outcomes.Methods: We searched Embase, Medline, Scopus, African Journals Online, CINAHL, Web of Science, Epistemonikos and Cochrane Central to August 2025 with no language restrictions. We included RCTs conducted in LMICs that compared any induction method to placebo or another induction method. We conducted a network meta-analysis using a Bayesian framework and ranking using odds ratios. The relative treatment efficacy ranking of the interventions was determined using the area under the cumulative ranking curve (SUCRA) values. Only trials with low risk of bias were included in the primary analysis.Findings: 207 studies were included (78 low risk, 37 moderate risk, 92 high risk) reporting outcomes for 37, 280 women and 60 induction methods. Low dose oral misoprostol is likely to be the most effective method for achieving vaginal birth within 24 hours (oral misoprostol <50 micrograms vs vaginal misoprostol <50 micrograms OR = 3.36, 95% Credible Interval (CrI) 1.25, 9.95), without increasing the caesarean birth rate (OR 0.98, 95% CrI 0.68, 1.48), NICU admission (OR 0.56, 95% CrI 0.24, 1.18) or Apgar scores <7 at 5 minutes (OR 0.50, 95% CrI 0.10, 2.31). However, compared with vaginal misoprostol<50 micrograms, oral misoprostol <50 micrograms may increase the chance of maternal side-effects including diarrhoea (OR =13.71, 95% CrI 1.44, 381.36) and nausea and vomiting (OR = 2.68, 95% CrI 1.44, 5.26).Interpretation: Low dose oral misoprostol appears to be most efficacious for achieving vaginal birth within 24 hours without increasing the incidence of adverse outcomes. For each woman selecting the best induction method involves a tradeoff between effectiveness, side-effects risks and benefits.
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWhich Is The Best Method For Induction Of Labour In Low- And Middle-Income Countries?: A Systematic Review And Network Meta-Analysis
Background: Globally, induction of labour rates and methods vary according to resource setting. Our aim is to identify the most effective induction of labour method for achieving vaginal birth within 24 hours in low- and middle-income settings without increasing adverse outcomes.Methods: We searched Embase, Medline, Scopus, African Journals Online, CINAHL, Web of Science, Epistemonikos and Cochrane Central to August 2025 with no language restrictions. We included RCTs conducted in LMICs that compared any induction method to placebo or another induction method. We conducted a network meta-analysis using a Bayesian framework and ranking using odds ratios. The relative treatment efficacy ranking of the interventions was determined using the area under the cumulative ranking curve (SUCRA) values. Only trials with low risk of bias were included in the primary analysis.Findings: 207 studies were included (78 low risk, 37 moderate risk, 92 high risk) reporting outcomes for 37, 280 women and 60 induction methods. Low dose oral misoprostol is likely to be the most effective method for achieving vaginal birth within 24 hours (oral misoprostol <50 micrograms vs vaginal misoprostol <50 micrograms OR = 3.36, 95% Credible Interval (CrI) 1.25, 9.95), without increasing the caesarean birth rate (OR 0.98, 95% CrI 0.68, 1.48), NICU admission (OR 0.56, 95% CrI 0.24, 1.18) or Apgar scores <7 at 5 minutes (OR 0.50, 95% CrI 0.10, 2.31). However, compared with vaginal misoprostol<50 micrograms, oral misoprostol <50 micrograms may increase the chance of maternal side-effects including diarrhoea (OR =13.71, 95% CrI 1.44, 381.36) and nausea and vomiting (OR = 2.68, 95% CrI 1.44, 5.26).Interpretation: Low dose oral misoprostol appears to be most efficacious for achieving vaginal birth within 24 hours without increasing the incidence of adverse outcomes. For each woman selecting the best induction method involves a tradeoff between effectiveness, side-effects risks and benefits.
- Open Access
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
Age at menarche and adverse pregnancy and perinatal outcomes: triangulating evidence from multivariable and Mendelian randomization analyses
Observational studies have suggested that a younger age at menarche is associated with increased risks of adverse pregnancy and perinatal outcomes. However, it is unclear whether these relationships are causal. We estimated the associations between age at menarche and 13 pre-specified pregnancy outcomes by using two approaches. We estimated observational associations in the Avon Longitudinal Study of Parents and Children (N = 9441) using multivariable regression accounting for educational attainment, ethnicity, maternal age, parity, offspring sex, and adiposity. We conducted two-sample Mendelian randomization (MR) using data from the Mendelian Randomization in Pregnancy (MR-PREG) collaboration (77 683–707 797 pregnancies) and multivariable MR (MVMR) accounting for genetically-proxied adiposity. Older age at menarche was associated with lower risks of hypertensive disorders of pregnancy, gestational hypertension, and preeclampsia, but accounting for adiposity attenuated these effects across approaches. For example, per 1-year older age at menarche, the odds ratio (OR) for hypertensive disorders of pregnancy was 0.88 (95% confidence interval (CI) : 0.84, 0.93) in inverse variance weighted MR and 0.95 (95% CI: 0.90, 1.01) in MVMR, while the observational association attenuated from OR = 0.91 (95% CI: 0.87, 0.94) to OR = 0.97 (95% CI: 0.93, 1.01). No clear evidence was found for the effects of age at menarche on small-for-gestational-age, low birthweight, post-term birth, or perinatal depression from either approach. For other outcomes evidence was limited by imprecision (very preterm birth, gestational diabetes) or inconsistent effects in sensitivity analyses (offspring birthweight, large-for-gestational-age, high birthweight, preterm birth). We find little robust evidence for causal effects of age at menarche on pregnancy outcomes. Effects of younger menarche on increased risks of hypertensive disorders of pregnancy may be driven by adiposity.
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
Open AccessAge at menarche and adverse pregnancy and perinatal outcomes: triangulating evidence from multivariable and Mendelian randomization analyses
Observational studies have suggested that a younger age at menarche is associated with increased risks of adverse pregnancy and perinatal outcomes. However, it is unclear whether these relationships are causal. We estimated the associations between age at menarche and 13 pre-specified pregnancy outcomes by using two approaches. We estimated observational associations in the Avon Longitudinal Study of Parents and Children (N = 9441) using multivariable regression accounting for educational attainment, ethnicity, maternal age, parity, offspring sex, and adiposity. We conducted two-sample Mendelian randomization (MR) using data from the Mendelian Randomization in Pregnancy (MR-PREG) collaboration (77 683–707 797 pregnancies) and multivariable MR (MVMR) accounting for genetically-proxied adiposity. Older age at menarche was associated with lower risks of hypertensive disorders of pregnancy, gestational hypertension, and preeclampsia, but accounting for adiposity attenuated these effects across approaches. For example, per 1-year older age at menarche, the odds ratio (OR) for hypertensive disorders of pregnancy was 0.88 (95% confidence interval (CI) : 0.84, 0.93) in inverse variance weighted MR and 0.95 (95% CI: 0.90, 1.01) in MVMR, while the observational association attenuated from OR = 0.91 (95% CI: 0.87, 0.94) to OR = 0.97 (95% CI: 0.93, 1.01). No clear evidence was found for the effects of age at menarche on small-for-gestational-age, low birthweight, post-term birth, or perinatal depression from either approach. For other outcomes evidence was limited by imprecision (very preterm birth, gestational diabetes) or inconsistent effects in sensitivity analyses (offspring birthweight, large-for-gestational-age, high birthweight, preterm birth). We find little robust evidence for causal effects of age at menarche on pregnancy outcomes. Effects of younger menarche on increased risks of hypertensive disorders of pregnancy may be driven by adiposity.
- Top Cited PapersOpen Access
Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
Purpose Adverse pregnancy and perinatal outcomes (APPOs), including pre-term birth, pre-eclampsia and gestational diabetes, can result in maternal and neonatal morbidity and mortality, parental anxiety and increased healthcare costs. A better understanding of the causes of APPOs is essential to inform lifestyle and pharmaceutical interventions for their prevention and management. Given the difficulty of undertaking randomised controlled trials in pregnant women, triangulating evidence from across methods with different sources of bias may improve causal inference for APPOs. The purpose of the Mendelian randomisation in pregnancy (MR-PREG) collaboration is to support such triangulation using genetic (eg, Mendelian randomisation (MR)) and non-genetic (eg, partner negative controls) approaches to investigate the causal effects of maternal exposures on a comprehensive set of APPOs. Participants The MR-PREG collaboration includes individual participant data from three birth cohorts (two from the UK and one from Norway) and UK Biobank, as well as summary data from FinnGen and publicly available genome-wide association studies (GWAS). Data have been harmonised across studies and currently include information on up to 35 APPOs in up to 707 797 women. Findings to date The main aims of MR-PREG are to strengthen the evidence base for (1) prevention, by advancing understanding of maternal lifestyle factors on APPOs, (2) the role of pre-conceptional health, by improving understanding of the effect of maternal pre-existing conditions on APPOs, and (3) treatments, by evaluating the efficacy and safety of existing medications used for pre-existing conditions, and by identifying and testing novel or repurposed therapies for APPOs. To date, our published work has mainly addressed aims 1 and 3. Examples include triangulation of evidence from MR, conventional multivariable regression and paternal negative control, showing that higher maternal body mass index increases the risk of multiple APPOs, as well as the identification of maternal circulating metabolites and proteins that may influence birth weight. Future plans Future priorities include increasing diversity within the MR-PREG collaboration by expanding representation of participants from non-European ancestries. We are also integrating molecular data, including circulating protein levels and placental transcriptomics, to better characterise the molecular mechanisms underlying APPOs. Additionally, we are using whole-exome and whole-genome sequencing to identify novel causal genes and to inform the prioritisation of candidate therapeutic targets for APPOs.
Top Cited PapersOpen AccessCohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
Purpose Adverse pregnancy and perinatal outcomes (APPOs), including pre-term birth, pre-eclampsia and gestational diabetes, can result in maternal and neonatal morbidity and mortality, parental anxiety and increased healthcare costs. A better understanding of the causes of APPOs is essential to inform lifestyle and pharmaceutical interventions for their prevention and management. Given the difficulty of undertaking randomised controlled trials in pregnant women, triangulating evidence from across methods with different sources of bias may improve causal inference for APPOs. The purpose of the Mendelian randomisation in pregnancy (MR-PREG) collaboration is to support such triangulation using genetic (eg, Mendelian randomisation (MR)) and non-genetic (eg, partner negative controls) approaches to investigate the causal effects of maternal exposures on a comprehensive set of APPOs. Participants The MR-PREG collaboration includes individual participant data from three birth cohorts (two from the UK and one from Norway) and UK Biobank, as well as summary data from FinnGen and publicly available genome-wide association studies (GWAS). Data have been harmonised across studies and currently include information on up to 35 APPOs in up to 707 797 women. Findings to date The main aims of MR-PREG are to strengthen the evidence base for (1) prevention, by advancing understanding of maternal lifestyle factors on APPOs, (2) the role of pre-conceptional health, by improving understanding of the effect of maternal pre-existing conditions on APPOs, and (3) treatments, by evaluating the efficacy and safety of existing medications used for pre-existing conditions, and by identifying and testing novel or repurposed therapies for APPOs. To date, our published work has mainly addressed aims 1 and 3. Examples include triangulation of evidence from MR, conventional multivariable regression and paternal negative control, showing that higher maternal body mass index increases the risk of multiple APPOs, as well as the identification of maternal circulating metabolites and proteins that may influence birth weight. Future plans Future priorities include increasing diversity within the MR-PREG collaboration by expanding representation of participants from non-European ancestries. We are also integrating molecular data, including circulating protein levels and placental transcriptomics, to better characterise the molecular mechanisms underlying APPOs. Additionally, we are using whole-exome and whole-genome sequencing to identify novel causal genes and to inform the prioritisation of candidate therapeutic targets for APPOs.
- Open Access
- 6 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Variation in gestational diabetes diagnosis and care practices in maternity services in three high-income countries; a cross-sectional survey
Background: There is limited international consensus about best diagnostic and care practices for gestational diabetes mellitus (GDM). This impacts consistency of care and perinatal outcomes. We aimed to explore GDM diagnostic and care practices in the UK, Ireland and Australia to better understand these variations and determine areas for improvement. Methods: We conducted a cross-sectional survey of healthcare professionals between August 2021-November 2022. The survey evaluated the use of GDM guidelines, associated diagnostic practices and post-diagnostic care. Data were descriptively analysed. Results: Sixty-three maternity centres were represented (35 England and Wales, 12 Ireland, 16 Australia). 94% of centres in England and Wales and Australia respectively used their national guidelines to select women for GDM testing, with a wider variety of guidelines used in Ireland. Over 80% of centres across countries test women for GDM based on risk-factors identified in early pregnancy. At 24–28 weeks’ gestation, 94% of Australian centres used universal screening as per national guidelines, compared with 3% of centres in England & Wales, and 50% in Ireland, where universal screening is not included in national guidelines. Risk factors used to select women for screening varied between countries and between centres within countries at both time points, with some centres using risk factors outside of their national guidelines. Diagnostic tests for GDM varied between countries and between centres within countries, and according to gestation and previous GDM. Insulin was the most common first-line treatment in Australia, whereas in Ireland and England and Wales it was Metformin. Birth was planned at differing gestations according to centre and country, and according to management strategy. Conclusions: GDM-related practices vary within and between Australia, Ireland and England and Wales. National guidelines are not adhered to in some centres, which could result in inconsistent care within countries, and could result in inequitable perinatal outcomes. Further research should address standardised, evidence-informed care and guideline implementation barriers.
- 6 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessVariation in gestational diabetes diagnosis and care practices in maternity services in three high-income countries; a cross-sectional survey
Background: There is limited international consensus about best diagnostic and care practices for gestational diabetes mellitus (GDM). This impacts consistency of care and perinatal outcomes. We aimed to explore GDM diagnostic and care practices in the UK, Ireland and Australia to better understand these variations and determine areas for improvement. Methods: We conducted a cross-sectional survey of healthcare professionals between August 2021-November 2022. The survey evaluated the use of GDM guidelines, associated diagnostic practices and post-diagnostic care. Data were descriptively analysed. Results: Sixty-three maternity centres were represented (35 England and Wales, 12 Ireland, 16 Australia). 94% of centres in England and Wales and Australia respectively used their national guidelines to select women for GDM testing, with a wider variety of guidelines used in Ireland. Over 80% of centres across countries test women for GDM based on risk-factors identified in early pregnancy. At 24–28 weeks’ gestation, 94% of Australian centres used universal screening as per national guidelines, compared with 3% of centres in England & Wales, and 50% in Ireland, where universal screening is not included in national guidelines. Risk factors used to select women for screening varied between countries and between centres within countries at both time points, with some centres using risk factors outside of their national guidelines. Diagnostic tests for GDM varied between countries and between centres within countries, and according to gestation and previous GDM. Insulin was the most common first-line treatment in Australia, whereas in Ireland and England and Wales it was Metformin. Birth was planned at differing gestations according to centre and country, and according to management strategy. Conclusions: GDM-related practices vary within and between Australia, Ireland and England and Wales. National guidelines are not adhered to in some centres, which could result in inconsistent care within countries, and could result in inequitable perinatal outcomes. Further research should address standardised, evidence-informed care and guideline implementation barriers.
- Open Access
- 28 July 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (13) , 2177-2185
How Should We Communicate Information Regarding Birth Choices to Women?: An Online Randomised Survey
Objective: To identify which risk communication graphics are easiest to understand when communicating risks surrounding birth, and investigate the effect of numeracy and health literacy on understanding. Design: Online survey with randomised content. Setting: UK. Population: Women and their partners, healthcare professionals and stakeholders in the UK. Methods: Seven candidate graphics (‘10‐person’, ‘100‐person’, ‘10‐circle’, ‘100‐circle’ icon arrays, ‘bar charts’, ‘pie charts’ and ‘words’) were co‐produced with a patient and public involvement group. These were used to develop seven online surveys. Participants were recruited using social media and adverts in participating hospitals. Each participant was randomised to see one of seven surveys, the survey questions remained the same, the graphics varied. Data were collected on risk perception, perceived ease of understanding and preference, alongside demographic factors, numeracy skills and health literacy. Main Outcome Measures: Objective comprehension and subjective preference for graphics. Results: There were 858 participants, 771 women/partners/parents and 87 healthcare professionals and stakeholders. 70% of participants answered all four numeracy questions correctly, and respondents reported high health literacy (76.5% can understand health material, 72.8% were comfortable completing medical forms). All graphics were understood; however, the ‘100‐person’ icon array elicited the best score when comparing two risks (mean score 97.5% compared to next best performing graphic 95.8%), 41% believed it was the easiest to understand and 36% selected it as the preferred graphic. Conclusions: All graphics are well understood. The ‘100‐person’ icon array scored best in terms of risk comparison and participant preference. Using this graphic may support high‐quality communication of risk in maternity care.
- 28 July 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (13) , 2177-2185
Open AccessHow Should We Communicate Information Regarding Birth Choices to Women?: An Online Randomised Survey
Objective: To identify which risk communication graphics are easiest to understand when communicating risks surrounding birth, and investigate the effect of numeracy and health literacy on understanding. Design: Online survey with randomised content. Setting: UK. Population: Women and their partners, healthcare professionals and stakeholders in the UK. Methods: Seven candidate graphics (‘10‐person’, ‘100‐person’, ‘10‐circle’, ‘100‐circle’ icon arrays, ‘bar charts’, ‘pie charts’ and ‘words’) were co‐produced with a patient and public involvement group. These were used to develop seven online surveys. Participants were recruited using social media and adverts in participating hospitals. Each participant was randomised to see one of seven surveys, the survey questions remained the same, the graphics varied. Data were collected on risk perception, perceived ease of understanding and preference, alongside demographic factors, numeracy skills and health literacy. Main Outcome Measures: Objective comprehension and subjective preference for graphics. Results: There were 858 participants, 771 women/partners/parents and 87 healthcare professionals and stakeholders. 70% of participants answered all four numeracy questions correctly, and respondents reported high health literacy (76.5% can understand health material, 72.8% were comfortable completing medical forms). All graphics were understood; however, the ‘100‐person’ icon array elicited the best score when comparing two risks (mean score 97.5% compared to next best performing graphic 95.8%), 41% believed it was the easiest to understand and 36% selected it as the preferred graphic. Conclusions: All graphics are well understood. The ‘100‐person’ icon array scored best in terms of risk comparison and participant preference. Using this graphic may support high‐quality communication of risk in maternity care.
- Open Access
Assessing the impact of maternal blood pressure during pregnancy on perinatal health: A wide-angled Mendelian randomization study
Background: Observational studies link high blood pressure in pregnancy to numerous adverse pregnancy and perinatal outcomes; however, findings may be affected by residual confounding or reverse causation. This study aimed to assess the causal effect of blood pressure during pregnancy on a range of pregnancy and perinatal outcomes. Methods: We performed two-sample Mendelian randomization (MR) to assess the effect of systolic and diastolic blood pressure (SBP/DBP) during pregnancy on 16 primary and eight secondary adverse pregnancy and perinatal outcomes. We obtained genetic association data from large-scale meta-analyses of genome-wide association studies involving predominantly European ancestry individuals for SBP/DBP (N=1,028,980), and pregnancy and perinatal outcomes (N=77,285–934,566). We used inverse-variance weighted (IVW) MR for main analyses and MR-Egger, weighted median, weighted mode, multivariable MR, and IVW adjusted for fetal genetic effects for sensitivity analyses. Results: A 10 mmHg higher genetically predicted maternal SBP increased the odds of gestational diabetes, induction of labour, low birth weight (LBW), small-for-gestational age (SGA), preterm birth (PTB), and neonatal intensive care unit (NICU) admission [OR ranging from 1.09 (95% CI: 1.04 to 1.14) for PTB to 1.33 (1.26 to 1.41) for LBW]; while decreasing the odds of high birth weight (HBW), large-for-gestational age (LGA), and post-term birth [OR ranging from 0.76 (0.69 to 0.83) for HBW to 0.94 (0.90 to 0.99) for post-term birth]. We did not find evidence that genetically predicted higher maternal SBP was related to miscarriage or stillbirth. Results for maternal DBP were similar to results for SBP. Overall, the main results were consistent across sensitivity analyses accounting for pleiotropic instruments and fetal genetic effects. Conclusions: Higher maternal blood pressure reduces gestation duration and fetal growth, and increases the risks of induction of labour, gestational diabetes and NICU admission. This and other emerging evidence highlight the value of interventions to control maternal blood pressure during pregnancy to reduce the burden of adverse pregnancy outcomes.
Open AccessAssessing the impact of maternal blood pressure during pregnancy on perinatal health: A wide-angled Mendelian randomization study
Background: Observational studies link high blood pressure in pregnancy to numerous adverse pregnancy and perinatal outcomes; however, findings may be affected by residual confounding or reverse causation. This study aimed to assess the causal effect of blood pressure during pregnancy on a range of pregnancy and perinatal outcomes. Methods: We performed two-sample Mendelian randomization (MR) to assess the effect of systolic and diastolic blood pressure (SBP/DBP) during pregnancy on 16 primary and eight secondary adverse pregnancy and perinatal outcomes. We obtained genetic association data from large-scale meta-analyses of genome-wide association studies involving predominantly European ancestry individuals for SBP/DBP (N=1,028,980), and pregnancy and perinatal outcomes (N=77,285–934,566). We used inverse-variance weighted (IVW) MR for main analyses and MR-Egger, weighted median, weighted mode, multivariable MR, and IVW adjusted for fetal genetic effects for sensitivity analyses. Results: A 10 mmHg higher genetically predicted maternal SBP increased the odds of gestational diabetes, induction of labour, low birth weight (LBW), small-for-gestational age (SGA), preterm birth (PTB), and neonatal intensive care unit (NICU) admission [OR ranging from 1.09 (95% CI: 1.04 to 1.14) for PTB to 1.33 (1.26 to 1.41) for LBW]; while decreasing the odds of high birth weight (HBW), large-for-gestational age (LGA), and post-term birth [OR ranging from 0.76 (0.69 to 0.83) for HBW to 0.94 (0.90 to 0.99) for post-term birth]. We did not find evidence that genetically predicted higher maternal SBP was related to miscarriage or stillbirth. Results for maternal DBP were similar to results for SBP. Overall, the main results were consistent across sensitivity analyses accounting for pleiotropic instruments and fetal genetic effects. Conclusions: Higher maternal blood pressure reduces gestation duration and fetal growth, and increases the risks of induction of labour, gestational diabetes and NICU admission. This and other emerging evidence highlight the value of interventions to control maternal blood pressure during pregnancy to reduce the burden of adverse pregnancy outcomes.
- Open Access
Women’s perspectives of decision-making for labour and birth: a qualitative antenatal-postnatal paired interview study
Objectives To understand and compare women’s antenatal and postnatal views on: (1) priorities for information provided about labour and delivery and (2) decision-making in labour and delivery. Design Qualitative interview study using repeat interviews at two time points: during pregnancy (≥13 weeks gestation); and after birth (≥6 weeks). Setting Large maternity hospital in the Southwest of England. Participants Pregnant women accessing antenatal care were purposively sampled and recruited antenatally by community midwives to ensure representation from different sociodemographic groups, with diverse experiences of low and high-risk care. Data collection Telephone interviews with a single researcher using a semistructured interview topic guide. Data analysis Interviews were audio recorded, transcribed verbatim, and qualitative thematic analysis was conducted using Braun and Clarke’s six-stage process. Results Twelve women participated (12 antenatal interviews; 10 follow-up postnatal interviews). Overall, women’s postnatal views were consistent with their antenatal views about what they wanted to know and the factors that influence decision-making. Three themes were generated. Theme 1 ‘Sources of information’ presents evidence of how women obtain and use information (sub-themes: ‘social influences’, ‘patient responsibility for information seeking’, ‘NHS vs non-NHS resources’). Theme 2 reports women’s views and experiences of ‘The influence of Healthcare Professionals in decision-making’ (sub-themes ‘patient and professional roles in decision-making’, ‘conflicting advice and preferences’, ‘taking authority in emergency decision-making’). The final theme, theme 3, ‘When, how, and what information women want’ shows women want time to process information (sub-themes ‘when: it’s definitely information and time’, ‘how: presentation of information’, ‘what: information required’). Cross-cutting all themes, we found an unmet need for information to be tailored to the individual. Conclusions Women understand decision-making during labour and birth is a dynamic process. Women can struggle with the volume, quality and timing of information available. In busy maternity settings, the challenge is to better equip women with the information they want, and health professionals with the information they need to provide for personalised care and shared decision-making. Antenatal interventions that warrant further research include decision aids, birth plans, and structured counselling using core information sets. Insights from both antenatal and postnatal perspectives will help inform their development.
Open AccessWomen’s perspectives of decision-making for labour and birth: a qualitative antenatal-postnatal paired interview study
Objectives To understand and compare women’s antenatal and postnatal views on: (1) priorities for information provided about labour and delivery and (2) decision-making in labour and delivery. Design Qualitative interview study using repeat interviews at two time points: during pregnancy (≥13 weeks gestation); and after birth (≥6 weeks). Setting Large maternity hospital in the Southwest of England. Participants Pregnant women accessing antenatal care were purposively sampled and recruited antenatally by community midwives to ensure representation from different sociodemographic groups, with diverse experiences of low and high-risk care. Data collection Telephone interviews with a single researcher using a semistructured interview topic guide. Data analysis Interviews were audio recorded, transcribed verbatim, and qualitative thematic analysis was conducted using Braun and Clarke’s six-stage process. Results Twelve women participated (12 antenatal interviews; 10 follow-up postnatal interviews). Overall, women’s postnatal views were consistent with their antenatal views about what they wanted to know and the factors that influence decision-making. Three themes were generated. Theme 1 ‘Sources of information’ presents evidence of how women obtain and use information (sub-themes: ‘social influences’, ‘patient responsibility for information seeking’, ‘NHS vs non-NHS resources’). Theme 2 reports women’s views and experiences of ‘The influence of Healthcare Professionals in decision-making’ (sub-themes ‘patient and professional roles in decision-making’, ‘conflicting advice and preferences’, ‘taking authority in emergency decision-making’). The final theme, theme 3, ‘When, how, and what information women want’ shows women want time to process information (sub-themes ‘when: it’s definitely information and time’, ‘how: presentation of information’, ‘what: information required’). Cross-cutting all themes, we found an unmet need for information to be tailored to the individual. Conclusions Women understand decision-making during labour and birth is a dynamic process. Women can struggle with the volume, quality and timing of information available. In busy maternity settings, the challenge is to better equip women with the information they want, and health professionals with the information they need to provide for personalised care and shared decision-making. Antenatal interventions that warrant further research include decision aids, birth plans, and structured counselling using core information sets. Insights from both antenatal and postnatal perspectives will help inform their development.
- Open Access
Cohort Profile: The Mendelian Randomization in Pregnancy (MR-PREG) collaboration - Improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
Purpose: Adverse pregnancy and perinatal outcomes (APPOs), including pre-term birth, pre-eclampsia, and gestational diabetes, can result in maternal and neonatal morbidity and mortality, parental anxiety, and increased health care costs. Better understanding of causes of APPOs is essential to inform lifestyle and pharmaceutical interventions for their prevention and management. Given the difficulty of undertaking randomised control trials in pregnant women, triangulating evidence from across different methods with different sources of bias could improve our understanding of the causes of APPOs. The purpose of the Mendelian Randomization in Pregnancy (MR-PREG) collaboration is to support triangulation of evidence from genetic (e.g., Mendelian randomization [MR]) and non-genetic (e.g., partner negative controls) methods to explore causal effects of maternal exposures on a comprehensive set of APPOs Participants: The MR-PREG collaboration includes individual participant data from three birth cohorts (two from the UK and one from Norway) and UK Biobank, and summary data from FinnGen and publicly available genome wide association studies (GWAS). We have harmonised data across studies so that currently includes exposures on up to 34 APPOs in up to 678,001 women. Findings to date: The main aims of MR-PREG are to improve the evidence base for 1) prevention, by advancing our understanding of maternal modifiable causes of APPOs, 2) better understanding of the effect of pre-existing conditions on APPOs, and 3) treatment, by advancing our knowledge of the efficacy and safety of existing medications that women may require for pre-existing conditions, and identifying and testing the efficacy and safety of novel medications, and those that might be repurposed to effectively and safely treat APPOs. To date, our published research mainly addresses aims 1 and 3; some examples include triangulation of evidence from MR, conventional multivariable regression and a paternal negative control, showing that higher maternal body mass index increases the risk of many APPOs, and identification of maternal circulating metabolites and proteins that may influence birthweight. Future Plans: Our future priorities include increasing diversity in the MR-PREG collaboration by expanding participant representation from non-European ancestries. We are also integrating molecular data, such as circulating protein levels and placental transcriptomics, to better understand the molecular mechanisms underlying APPOs. Additionally, we are using exome and whole-genome sequencing to identify novel causal genes for APPOs and advance our knowledge on candidate targets for APPOs. Strengths and limitations: We have curated data for 34 APPOs and harmonized data across multiple studies to support large-scale investigations of causes of APPOs. The scope and type of the data supports triangulation of evidence from a range of genetic and non-genetic methods, with different unrelated sources of bias, to identify causes of APPOs. Over the coming year we will enhance the data to enable identification of molecular mechanism underlying APPOs. MR-PREG has limited power to detect causal effects on rarer APPOs, such as congenital anomalies and low Apgar scores at 5 minutes, particularly when using genetic methods. Future work will include larger samples and rare genetic variant data. Participants are mostly of European ancestry; future efforts will be focussed on diversifying the ancestry representation in the data.
Open AccessCohort Profile: The Mendelian Randomization in Pregnancy (MR-PREG) collaboration - Improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
Purpose: Adverse pregnancy and perinatal outcomes (APPOs), including pre-term birth, pre-eclampsia, and gestational diabetes, can result in maternal and neonatal morbidity and mortality, parental anxiety, and increased health care costs. Better understanding of causes of APPOs is essential to inform lifestyle and pharmaceutical interventions for their prevention and management. Given the difficulty of undertaking randomised control trials in pregnant women, triangulating evidence from across different methods with different sources of bias could improve our understanding of the causes of APPOs. The purpose of the Mendelian Randomization in Pregnancy (MR-PREG) collaboration is to support triangulation of evidence from genetic (e.g., Mendelian randomization [MR]) and non-genetic (e.g., partner negative controls) methods to explore causal effects of maternal exposures on a comprehensive set of APPOs Participants: The MR-PREG collaboration includes individual participant data from three birth cohorts (two from the UK and one from Norway) and UK Biobank, and summary data from FinnGen and publicly available genome wide association studies (GWAS). We have harmonised data across studies so that currently includes exposures on up to 34 APPOs in up to 678,001 women. Findings to date: The main aims of MR-PREG are to improve the evidence base for 1) prevention, by advancing our understanding of maternal modifiable causes of APPOs, 2) better understanding of the effect of pre-existing conditions on APPOs, and 3) treatment, by advancing our knowledge of the efficacy and safety of existing medications that women may require for pre-existing conditions, and identifying and testing the efficacy and safety of novel medications, and those that might be repurposed to effectively and safely treat APPOs. To date, our published research mainly addresses aims 1 and 3; some examples include triangulation of evidence from MR, conventional multivariable regression and a paternal negative control, showing that higher maternal body mass index increases the risk of many APPOs, and identification of maternal circulating metabolites and proteins that may influence birthweight. Future Plans: Our future priorities include increasing diversity in the MR-PREG collaboration by expanding participant representation from non-European ancestries. We are also integrating molecular data, such as circulating protein levels and placental transcriptomics, to better understand the molecular mechanisms underlying APPOs. Additionally, we are using exome and whole-genome sequencing to identify novel causal genes for APPOs and advance our knowledge on candidate targets for APPOs. Strengths and limitations: We have curated data for 34 APPOs and harmonized data across multiple studies to support large-scale investigations of causes of APPOs. The scope and type of the data supports triangulation of evidence from a range of genetic and non-genetic methods, with different unrelated sources of bias, to identify causes of APPOs. Over the coming year we will enhance the data to enable identification of molecular mechanism underlying APPOs. MR-PREG has limited power to detect causal effects on rarer APPOs, such as congenital anomalies and low Apgar scores at 5 minutes, particularly when using genetic methods. Future work will include larger samples and rare genetic variant data. Participants are mostly of European ancestry; future efforts will be focussed on diversifying the ancestry representation in the data.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e030823
Preterm Birth and Cardiometabolic Health Trajectories From Birth to Adulthood: The Avon Longitudinal Study of Parents and Children
Background: Adults who were born prematurely (<37 weeks’ gestation) are at increased cardiovascular disease risk, but it is unclear when in the life course this risk emerges. Our aim was to compare trajectories of multiple cardiometabolic risk factors from childhood to early adulthood between those who had and had not been born preterm. Methods and Results: Multilevel models were used to compare trajectories from early childhood (<9 years) to age 25 years of body mass index, fat and lean mass, systolic and diastolic blood pressure, lipids, glucose, and insulin, between individuals born preterm (N=311–676; range, 25–36 weeks’ gestation) and term (N=4973–10 534) in a UK birth cohort study. We also investigated gestational age as a continuum. In children born preterm (versus term), systolic and diastolic blood pressures were higher at age 7 years (mean predicted differences, 0.7 [95% CI, −0.2 to 1.6] mm Hg and 0.6 [95% CI, −0.04 to 1.3] mm Hg, respectively). By age 18 years, the difference in systolic blood pressure persisted (1.9 [95% CI, 0.8–3.1] mm Hg) and in diastolic blood pressure (0.1 [95% CI, −0.7 to 1.0 mm Hg]) disappeared. By age 25 years, this difference in systolic blood pressure began to attenuate towards the null (0.9 [95% CI, −0.5 to 2.3] mm Hg). Participants born preterm (versus term) had lower body mass index between ages 7 and 18 years, but by age 25 years, there was no difference. Fat and lean mass trajectories were consistent with body mass index. High‐density lipoprotein cholesterol was higher and triglycerides lower at birth, in those born preterm, but this difference also disappeared by age 25 years. There was no evidence of differences in glucose and insulin. Conclusions: Few, modest differences in cardiometabolic health were found in those born preterm versus term. All disappeared by age 25 years, except the small difference in systolic blood pressure. Longer follow‐up is needed to establish if and when cardiometabolic health trajectories diverge between these 2 groups.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e030823
Open AccessPreterm Birth and Cardiometabolic Health Trajectories From Birth to Adulthood: The Avon Longitudinal Study of Parents and Children
Background: Adults who were born prematurely (<37 weeks’ gestation) are at increased cardiovascular disease risk, but it is unclear when in the life course this risk emerges. Our aim was to compare trajectories of multiple cardiometabolic risk factors from childhood to early adulthood between those who had and had not been born preterm. Methods and Results: Multilevel models were used to compare trajectories from early childhood (<9 years) to age 25 years of body mass index, fat and lean mass, systolic and diastolic blood pressure, lipids, glucose, and insulin, between individuals born preterm (N=311–676; range, 25–36 weeks’ gestation) and term (N=4973–10 534) in a UK birth cohort study. We also investigated gestational age as a continuum. In children born preterm (versus term), systolic and diastolic blood pressures were higher at age 7 years (mean predicted differences, 0.7 [95% CI, −0.2 to 1.6] mm Hg and 0.6 [95% CI, −0.04 to 1.3] mm Hg, respectively). By age 18 years, the difference in systolic blood pressure persisted (1.9 [95% CI, 0.8–3.1] mm Hg) and in diastolic blood pressure (0.1 [95% CI, −0.7 to 1.0 mm Hg]) disappeared. By age 25 years, this difference in systolic blood pressure began to attenuate towards the null (0.9 [95% CI, −0.5 to 2.3] mm Hg). Participants born preterm (versus term) had lower body mass index between ages 7 and 18 years, but by age 25 years, there was no difference. Fat and lean mass trajectories were consistent with body mass index. High‐density lipoprotein cholesterol was higher and triglycerides lower at birth, in those born preterm, but this difference also disappeared by age 25 years. There was no evidence of differences in glucose and insulin. Conclusions: Few, modest differences in cardiometabolic health were found in those born preterm versus term. All disappeared by age 25 years, except the small difference in systolic blood pressure. Longer follow‐up is needed to establish if and when cardiometabolic health trajectories diverge between these 2 groups.
- Open Access
- 10 September 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (3) , 231-240
Systematic Review of Clinical Prediction Models for the Risk of Emergency Caesarean Births
Background: Globally, caesarean births (CB), including emergency caesareans births (EmCB), are rising. It is estimated that nearly a third of all births will be CB by 2030.Objectives: Identify and summarise the results from studies developing and validating prognostic multivariable models predicting the risk of EmCBs. Ultimately understanding the accuracy of their development, and whether they are operationalised for use in routine clinical practice.Search Strategy: Studies were identified using databases: MEDLINE, CINAHL, Cochrane Central and Scopus with a search strategy tailored to models predicting EmCBs.Selection Criteria: Prospective studies developing and validating clinical prediction models, with two or more covariates, to predict risk of EmCB.Data Collection and Analysis: Data were extracted onto a proforma using the Prediction model Risk Of Bias ASsessment Tool (PROBAST).Results: In total, 8083 studies resulted in 56 unique prediction modelling studies and seven validating studies, with a total of 121 different predictors. Frequently occurring predictors included maternal height, maternal age, parity, BMI and gestational age. PROBAST highlighted 33 studies with low overall bias, and these all internally validated their model. Thirteen studies externally validated; only eight of these were graded an overall low risk of bias. Six models offered applications that could be readily used, but only one provided enough time to offer a planned caesarean birth (pCB). These well‐refined models have not been recalibrated since development. Only one model, developed in a relatively low‐risk population, with data collected a decade ago, remains useful at 36 weeks for arranging a pCB.Conclusion: To improve personalised clinical conversations, there is a pressing need for a model that accurately predicts the timely risk of an EmCB for women across diverse clinical backgrounds.Trial Registration: PROSPERO registration number: CRD42023384439.
- 10 September 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (3) , 231-240
Open AccessSystematic Review of Clinical Prediction Models for the Risk of Emergency Caesarean Births
Background: Globally, caesarean births (CB), including emergency caesareans births (EmCB), are rising. It is estimated that nearly a third of all births will be CB by 2030.Objectives: Identify and summarise the results from studies developing and validating prognostic multivariable models predicting the risk of EmCBs. Ultimately understanding the accuracy of their development, and whether they are operationalised for use in routine clinical practice.Search Strategy: Studies were identified using databases: MEDLINE, CINAHL, Cochrane Central and Scopus with a search strategy tailored to models predicting EmCBs.Selection Criteria: Prospective studies developing and validating clinical prediction models, with two or more covariates, to predict risk of EmCB.Data Collection and Analysis: Data were extracted onto a proforma using the Prediction model Risk Of Bias ASsessment Tool (PROBAST).Results: In total, 8083 studies resulted in 56 unique prediction modelling studies and seven validating studies, with a total of 121 different predictors. Frequently occurring predictors included maternal height, maternal age, parity, BMI and gestational age. PROBAST highlighted 33 studies with low overall bias, and these all internally validated their model. Thirteen studies externally validated; only eight of these were graded an overall low risk of bias. Six models offered applications that could be readily used, but only one provided enough time to offer a planned caesarean birth (pCB). These well‐refined models have not been recalibrated since development. Only one model, developed in a relatively low‐risk population, with data collected a decade ago, remains useful at 36 weeks for arranging a pCB.Conclusion: To improve personalised clinical conversations, there is a pressing need for a model that accurately predicts the timely risk of an EmCB for women across diverse clinical backgrounds.Trial Registration: PROSPERO registration number: CRD42023384439.